{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:17:03Z","timestamp":1767665823608},"reference-count":58,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,1,21]],"date-time":"2002-01-21T00:00:00Z","timestamp":1011571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many striatal dopaminergic markers are available for estimating the degree of the nigrostriatal lesion by MPTP\/MPP<jats:sup>+<\/jats:sup>, but the changes of these markers are not perfectly matched. In this study we investigated different striatal markers and determined which ones closely reflected the nigrostriatal alteration. The <jats:italic>in\u2003vivo<\/jats:italic> binding of (E)\u2010<jats:italic>N\u2010<\/jats:italic>(3\u2010iodoprop\u20102\u2010enyl)\u2010\t2\u2010\u03b2\u2010carbomethoxy\u20103\u03b2\u2010(4\u2032\u2010methylphenyl)nortropane (PE2I), a selective and potent inhibitor of the neuronal dopamine transporter (DAT) was considered as the reference index of injury of striatal dopaminergic nerve\u2010endings. Rats received a 10\u2010\u00b5g MPP<jats:sup>+<\/jats:sup> injection in the right substantia nigra and were killed at 7\u2003days after lesion. The results were as follows: (i) a decrease (66%) of the biodistribution of [<jats:sup>125<\/jats:sup>I]PE2I; (ii) a great reduction of the DAT expression measured by the binding of [<jats:sup>125<\/jats:sup>I]PE2I in striatal membranes (<jats:italic>B<\/jats:italic><jats:sub>max<\/jats:sub> decreased by 54%) and in cerebral slices (88%); (iii) an 80% inhibition of the vesicular monoamine transporter expression revealed by the binding of [<jats:sup>3<\/jats:sup>H]dihydrotetrabenazine in cerebral slices; (iv) a robust decrease in the quantity of DA and its metabolites (about 50\u201360%); (v) a slight modification of the DAT activity with a decreased number of functional sites (<jats:italic>V<\/jats:italic><jats:sub>max<\/jats:sub> decreased by 12%, <jats:italic>p<\/jats:italic>\u2003&lt;\u20030.05) without change of the affinity in striatal synaptosomes. Among these markers the binding of [<jats:sup>125<\/jats:sup>I]PE2I in membrane homogenates and the content of DA, and its metabolites, in striatum could be the most relevant <jats:italic>in\u2003vitro<\/jats:italic> indexes of the degenerative state of the nigrostriatal pathway after MPP<jats:sup>+<\/jats:sup> lesion.<\/jats:p>","DOI":"10.1046\/j.0022-3042.2001.00743.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T06:58:49Z","timestamp":1047452329000},"page":"365-374","source":"Crossref","is-referenced-by-count":17,"title":["Relevance of different striatal markers in assessment of the MPP<sup>+<\/sup>\u2010induced dopaminergic nigrostriatal injury in rat"],"prefix":"10.1111","volume":"80","author":[{"given":"St\u00e9phanie","family":"Barc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guyl\u00e8ne","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Barrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucette","family":"Garreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Guilloteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Fauconneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(86)90573-X"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)01300-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)02567-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)00531-3"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(89)90563-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2000.0308"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199902)31:2<134::AID-SYN6>3.0.CO;2-V"},{"key":"e_1_2_8_9_1","first-page":"648","article-title":"Pharmacological characterization of (E)\u2010N\u2010(3\u2010iodoprop\u20102\u2010enyl)\u20102\u03b2\u2010carbomethoxy\u20103\u03b2\u2010(4\u2032\u2010methylphenyl) nortropane as a selective and potent inhibitor of the neuronal dopamine transporter","volume":"291","author":"Chalon S.","year":"1999","journal-title":"J. Pharm. Exp. Ther."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90221-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.50.35794"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(00)03311-4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(95)02161-2"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm960795d"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(00)02999-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400609"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01291788"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/379606a0"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1966.tb09873.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(19990601)32:3<153::AID-SYN2>3.0.CO;2-X"},{"key":"e_1_2_8_21_1","first-page":"34","article-title":"Early\u2010stage loss of dopamine uptake\u2010site binding in MPTP\u2010treated monkeys","volume":"60","author":"Graybiel A. M.","year":"1993","journal-title":"Adv. Neurol."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(97)00224-2"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.1998.0366"},{"key":"e_1_2_8_24_1","unstructured":"HarikS. I. SchmidleyJ. W. IacofanoL. A. BlueP. AroraP. K.andSayreL. M.(1987) On the mechanisms underlying 1\u2010methyl\u20104\u2010phenyl\u20101 2 3 6\u2010tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1\u2010methyl\u20104phenyl\u20101 2 3 6\u2013tetrahydropyridine its metabolite and their analogs in the rat.J. Pharm. Exp. Ther. 241 669\u2013676."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(85)90227-7"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03159727"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.0742217.x"},{"key":"e_1_2_8_28_1","first-page":"746","article-title":"The effects of various salts, temperature and the alkaloids veratridine and batrachotoxin on the uptake of 3H\u2010dopamine into synaptosomes from rat striatum","volume":"10","author":"Holz R. W.","year":"1974","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/1055-8330(95)90015-2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(97)00101-7"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(20000315)35:4<250::AID-SYN2>3.0.CO;2-S"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.11.030188.000501"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050254"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6823561"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199504040-00007"},{"key":"e_1_2_8_36_1","first-page":"686","article-title":"Characterization of a tropane radioligand, [3H]2\u03b2\u2010propanoyl\u20103\u03b2\u2010(4\u2010tolyl) tropane ([3H]PTT), for dopamine transport sites in rat brain","volume":"293","author":"Letchworth S. R.","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(00)02926-7"},{"key":"e_1_2_8_38_1","first-page":"439","article-title":"Neurotransmitter transporters in the central nervous system","volume":"51","author":"Masson J.","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)91686-B"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0730750.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90664-4"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)91141-8"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00082-2"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(85)90146-8"},{"key":"e_1_2_8_45_1","first-page":"348","article-title":"GDNF protects against 6\u2010OHDA nigrostriatal lesion: in vivo with microdialysis and PET","volume":"7","author":"Opacka\u2010Juffry J.","year":"1995","journal-title":"Neuroreport"},{"key":"e_1_2_8_46_1","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos G.","year":"1999"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)91094-4"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(77)90043-4"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<120::AID-SYN5>3.0.CO;2-Y"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.10.4565"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90486-F"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050406"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(96)00040-8"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90354-6"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01245141"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.00062.x"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00545-3"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.16-10-03507.1996"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)32071-X"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0022-3042.2001.00743.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0022-3042.2001.00743.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:46:01Z","timestamp":1697553961000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.0022-3042.2001.00743.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1,21]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1046\/j.0022-3042.2001.00743.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0022-3042.2001.00743.x","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1,21]]}}}